The Pharmacology of Tardive Dyskinesias
Abstract
The activity of dopamine at certain striatal dopamine receptors is related to the appearance of tardive dyskinesias in man. By analogy to Huntington's chorea and L-dopa-induced dyskinesias in parkinsonism, it appears that tardive dyskinesias are related to increased responsiveness of dopamine receptor sites as a result of neuroleptic-induced denervation hypersensitivity. It has been demonstrated that anticholinergic drugs worsen tardive dyskinesias in patients who have this disorder. It also appears that anticholinergic drugs decrease the threshold for tardive dyskinesias and thereby increase the incidence of this disorder. This implies that centrally active anticholinergic agents should not be used as a routine adjunct to neuroleptic therapy.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
